| Abstract |
[Abstract] Objective to analyze the effect of butylphthalide on patients with acute cerebral thrombosis complicated with depression and the changes of plasma lysophosphatidic acid (LPA).Methods The clinical data of 128 patients with acute cerebral thrombosis complicated with depression from January 2015 to January 2018 were analyzed and divided into two groups. The control group was treated by oral sertraline hydrochloride on the basis of routine treatment, and the observation group was treated with butyphthalide on the basis of the control group. The clinical efficacy of the two groups was analyzed.Results There was no significant difference in LPA, matrix metalloproteinase-9 (MMP-9), plasma thromboglobulin (β-TG),) IV factor (PF4) and coagulation function between the two groups before treatment (P > 0. 05). The levels of LPA,MMP-9, β-TG,PF4,APTT,FIB,D-D and PT in the observation group were lower than those in the control group (P < 0. 05). Before treatment, the (NIHSS), of the American National Institutes of Health Stroke scale was higher in the two groups (P < 0. 05). Motor function rating scale (Fugl-Meyer) There was no significant difference in the (SDS) score of Barthel index rating scale (BI), anxiety self-rating scale (SAS), self-rating depression scale between the two groups (P > 0. 05). After treatment, the Fugl-Meyer,BI score and NIHSS,SAS,SDS in the observation group were higher than those in the control group (P < 0. 05).Conclusion Butyphthalide treatment for patients with acute cerebral thrombosis combined with depression can reduce the level of LPA, improve the neurological function defect, relieve anxiety and depression symptoms, and improve the quality of life of the patients.
|